Genentech, Inc. has plans to acquire Tanox, Inc., a biotechnology company, for a total cash value of approximately $919 million. Tanox specializes in the discovery and development of biotherapeutics based on monoclonal antibody technology. The two companies have been working together in collaboration with Novartis since 1996 to develop and commercialize Xolair, an anti-IgE monoclonal antibody approved by the FDA in 2003 as a treatment for patients with moderate-to-severe allergic asthma. U...